Serotonin 5-HT1 Receptor Agonists
"Serotonin 5-HT1 Receptor Agonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Endogenous compounds and drugs that specifically stimulate SEROTONIN 5-HT1 RECEPTORS. Included under this heading are agonists for one or more of the specific 5-HT1 receptor subtypes.
| Descriptor ID |
D058825
|
| MeSH Number(s) |
D27.505.519.625.850.800.100 D27.505.696.577.850.800.100
|
| Concept/Terms |
Serotonin 5-HT1 Receptor Agonists- Serotonin 5-HT1 Receptor Agonists
- Serotonin 5 HT1 Receptor Agonists
- 5-HT1 Agonist
- 5 HT1 Agonist
- Agonist, 5-HT1
- 5-HT1 Agonists
- 5 HT1 Agonists
- Agonists, 5-HT1
Serotonin 5-HT1B-D Agonists- Serotonin 5-HT1B-D Agonists
- 5-HT1B-D Agonists, Serotonin
- Agonists, Serotonin 5-HT1B-D
- Serotonin 5 HT1B D Agonists
- 5-HT1B-D Agonist
- 5 HT1B D Agonist
- Agonist, 5-HT1B-D
|
Below are MeSH descriptors whose meaning is more general than "Serotonin 5-HT1 Receptor Agonists".
Below are MeSH descriptors whose meaning is more specific than "Serotonin 5-HT1 Receptor Agonists".
This graph shows the total number of publications written about "Serotonin 5-HT1 Receptor Agonists" by people in this website by year, and whether "Serotonin 5-HT1 Receptor Agonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Serotonin 5-HT1 Receptor Agonists" by people in Profiles.
-
Ward SJ, McAllister SD, Kawamura R, Murase R, Neelakantan H, Walker EA. Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy. Br J Pharmacol. 2014 Feb; 171(3):636-45.
-
Silberstein SD, Newman LC, Marmura MJ, Nahas SJ, Farr SJ. Efficacy endpoints in migraine clinical trials: the importance of assessing freedom from pain. Curr Med Res Opin. 2013 Jul; 29(7):861-7.
-
Merry DE. Attacking the flank: targeting new pathways in SBMA. Nat Med. 2012 Oct; 18(10):1461-3.